SMN1 and amyotrophic lateral sclerosis: SMA has served as a proof of concept for antisense oligonucleotide and gene therapy, with several other disorders now in line for similar drug trials, such as amyotrophic lateral sclerosis (ALS) and Duchenne’s Muscular Dystrophy [21].